It has already been shown that mutations in ELAVL4 are associated with an earlier onset of Parkinson’s disease [25], and the dysregulated expression of its known target, GAP43, has been observed in the frontal cortices and hippocampi of individuals with schizophrenia [26]. Here, GAP43 is linked to schizophrenia.